Update shared on23 Sep 2025
Fair value Increased 6.16%Alnylam Pharmaceuticals’ price target was raised to $447.15 as analysts cited accelerating Amvuttra sales, positive clinical progress, robust financial execution, and increased revenue forecasts, reflecting growing confidence in the company’s commercial momentum and pipeline.
Analyst Commentary
- Strong commercial momentum for Amvuttra, particularly in ATTR-CM, with sales trends and script data consistently exceeding expectations.
- Encouraging clinical updates, notably from Phase 2 KARDIA-3 data for zilebesiran in hypertension, reinforcing belief in Alnylam's pipeline despite some endpoints not reaching statistical significance.
- Successful financial execution, highlighted by a $575M convertible note offering, supporting long-term expansion and commercial strategy.
- Upward revisions to company guidance and revenue forecasts, alongside reiterated outlook for robust total product revenues through 2025.
- Bullish analysts see Alnylam’s siRNA platform and first-to-market positioning in TTR silencing as creating significant long-term market opportunities not yet fully reflected in valuation.
What's in the News
- JPMorgan raised Alnylam’s price target to $348 (from $338) and maintains an Overweight rating, citing increased forecasts for Amvuttra in transthyretin amyloid cardiomyopathy ahead of Q2 results and expected guidance raises for the TTR franchise (Periodicals).
- Alnylam announced strong long-term data from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran), showing sustained efficacy and safety, significant reductions in all-cause mortality and cardiovascular events, and quality of life improvements in ATTR-CM patients; these outcomes supported recent approvals in multiple international markets (Key Developments).
- FY2025 revenue guidance was raised, with total net product revenues now projected at $2.65–$2.8 billion, up from $2.05–$2.25 billion, and collaborations/royalty revenues guided at $650–$750 million (Key Developments).
- Alnylam joined the Alliance for Genomic Discovery to expand the use of clinical genomic data for drug target discovery in autoimmune and neurodegenerative diseases, aligning with industry leaders and enhancing pipeline innovation (Key Developments).
- In June 2025, Alnylam was dropped from several Russell value and small-cap indices despite other positive developments, which may impact investor flows (Key Developments).
Valuation Changes
Summary of Valuation Changes for Alnylam Pharmaceuticals
- The Consensus Analyst Price Target has risen from $421.20 to $447.15.
- The Consensus Revenue Growth forecasts for Alnylam Pharmaceuticals has risen slightly from 41.6% per annum to 42.5% per annum.
- The Future P/E for Alnylam Pharmaceuticals has risen slightly from 37.36x to 38.18x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.